Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

208 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Chemotherapy-Free Initial Treatment of Advanced Indolent Lymphoma Has Durable Effect With Low Toxicity: Results From Two Nordic Lymphoma Group Trials With More Than 10 Years of Follow-Up.
Lockmer S, Østenstad B, Hagberg H, Holte H, Johansson AS, Wahlin BE, Wader KF, Steen CB, Meyer P, Maisenhølder M, Smedby KE, Brown P, Kimby E. Lockmer S, et al. Among authors: kimby e. J Clin Oncol. 2018 Oct 4:JCO1800262. doi: 10.1200/JCO.18.00262. Online ahead of print. J Clin Oncol. 2018. PMID: 30285560
Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: a randomized phase II study from the Nordic Lymphoma Group.
Kimby E, Jurlander J, Geisler C, Hagberg H, Holte H, Lehtinen T, Ostenstad B, Hansen M, Osterborg A, Lindén O, Sundström C; Nordic Lymphoma Group. Kimby E, et al. Leuk Lymphoma. 2008 Jan;49(1):102-12. doi: 10.1080/10428190701704647. Leuk Lymphoma. 2008. PMID: 18203019 Clinical Trial.
Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group.
Geisler CH, Kolstad A, Laurell A, Andersen NS, Pedersen LB, Jerkeman M, Eriksson M, Nordström M, Kimby E, Boesen AM, Kuittinen O, Lauritzsen GF, Nilsson-Ehle H, Ralfkiaer E, Akerman M, Ehinger M, Sundström C, Langholm R, Delabie J, Karjalainen-Lindsberg ML, Brown P, Elonen E; Nordic Lymphoma Group. Geisler CH, et al. Among authors: kimby e. Blood. 2008 Oct 1;112(7):2687-93. doi: 10.1182/blood-2008-03-147025. Epub 2008 Jul 14. Blood. 2008. PMID: 18625886 Free PMC article. Clinical Trial.
A unifying microenvironment model in follicular lymphoma: outcome is predicted by programmed death-1--positive, regulatory, cytotoxic, and helper T cells and macrophages.
Wahlin BE, Aggarwal M, Montes-Moreno S, Gonzalez LF, Roncador G, Sanchez-Verde L, Christensson B, Sander B, Kimby E. Wahlin BE, et al. Among authors: kimby e. Clin Cancer Res. 2010 Jan 15;16(2):637-50. doi: 10.1158/1078-0432.CCR-09-2487. Epub 2010 Jan 12. Clin Cancer Res. 2010. PMID: 20068089
BCL-2/IgH polymerase chain reaction status at the end of induction treatment is not predictive for progression-free survival in relapsed/resistant follicular lymphoma: results of a prospective randomized EORTC 20981 phase III intergroup study.
van Oers MH, Tönnissen E, Van Glabbeke M, Giurgea L, Jansen JH, Klasa R, Marcus RE, Wolf M, Kimby E, Vranovsky A, Holte H, Hagenbeek A, van der Reijden BA. van Oers MH, et al. Among authors: kimby e. J Clin Oncol. 2010 May 1;28(13):2246-52. doi: 10.1200/JCO.2009.25.0852. Epub 2010 Apr 5. J Clin Oncol. 2010. PMID: 20368567 Clinical Trial.
Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study.
van Oers MH, Van Glabbeke M, Giurgea L, Klasa R, Marcus RE, Wolf M, Kimby E, van t Veer M, Vranovsky A, Holte H, Hagenbeek A. van Oers MH, et al. Among authors: kimby e. J Clin Oncol. 2010 Jun 10;28(17):2853-8. doi: 10.1200/JCO.2009.26.5827. Epub 2010 May 3. J Clin Oncol. 2010. PMID: 20439641 Free PMC article. Clinical Trial.
T cells in tumors and blood predict outcome in follicular lymphoma treated with rituximab.
Wahlin BE, Sundström C, Holte H, Hagberg H, Erlanson M, Nilsson-Ehle H, Lindén O, Nordström M, Ostenstad B, Geisler CH, Brown Pde N, Lehtinen T, Maisenhölder M, Tierens AM, Sander B, Christensson B, Kimby E. Wahlin BE, et al. Among authors: kimby e. Clin Cancer Res. 2011 Jun 15;17(12):4136-44. doi: 10.1158/1078-0432.CCR-11-0264. Epub 2011 Apr 25. Clin Cancer Res. 2011. PMID: 21518780 Free article.
208 results